Tema GLP-1, Obesity & Cardiometabolic ETF's Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) has disclosed 44 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2024-08-31. The current portfolio value is calculated to be $87.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 27%.
Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS)'s
Total Assets is $87.91 Mil , Total Liabilities is $71,420.00 , Net Assets is $87.84 Mil.
In Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS)'s current portfolio as of 2024-08-31, the top 5 holdings are
Amgen Inc (AMGN), Eli Lilly and Co (LLY), Alnylam Pharmaceuticals Inc (ALNY), Vertex Pharmaceuticals Inc (VRTX) and Novo Nordisk AS (OCSE:NOVO B),
not including call and put options.
Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Tema GLP-1, Obesity & Cardiometabolic ETF.